# Safety, Feasibility, and User Experience of Automated Insulin Delivery Systems During Hajj (Muslim Pilgrimage)

**Authors:** Mohammed E. Al-Sofiani

PMC · DOI: 10.3390/jcm15020860 · Journal of Clinical Medicine · 2026-01-21

## TL;DR

This study shows that automated insulin delivery systems can safely help people with type 1 diabetes manage their condition during the physically demanding Hajj pilgrimage.

## Contribution

This is the first study to evaluate automated insulin delivery systems during Hajj, a unique and challenging setting for diabetes management.

## Key findings

- Glycemic control remained stable during Hajj with automated insulin delivery systems.
- There were no acute diabetes-related complications during the pilgrimage.
- Participants reported increased confidence and peace of mind using the systems.

## Abstract

Background/Objectives: Performing Hajj, the annual Islamic pilgrimage to Mecca and one of the world’s largest mass gatherings, involves considerable physical exertion in high temperatures and presents unique challenges for people with type 1 diabetes (PWT1D). We examined the feasibility, safety, and user experience of automated insulin delivery (AID) systems during Hajj. Methods: This mixed-methods study evaluated six PWT1D who used an AID pump (2 MiniMed 780G, 2 Medtrum, 1 OmniPod 5, and 1 Open-source AID) while performing Hajj in 2024–2025. Pump and CGM-derived metrics were compared across pre-Hajj, during Hajj, and post-Hajj periods. A structured survey captured participants’ experiences, challenges, and recommendations for AID use during Hajj. Results: The average percent time in range (TIR) remained stable from pre- to during Hajj (54.98 to 54.18, p > 0.05) and significantly increased post-Hajj (62.62, p < 0.05). The percent time above range (TAR > 180) and Glycemia Risk Index significantly decreased from pre- to post-Hajj (28.34 to 26.28 and 50.3 to 19.3, respectively, both p < 0.05). The percent time below range (TBR) remained low (<1%) across the three periods with no incidence of acute diabetes-related complications. Participants emphasized increased confidence and peace of mind with AID use and reported challenges related to heat exposure, prolonged walking, and lack of awareness regarding diabetes technology among HCPs. Conclusions: The use of AID during Hajj appeared to be safe and effective for PWT1D in our study, maintaining stable glycemic control under physically demanding conditions. As the first study to evaluate AID use during Hajj, our findings call for larger studies to explore the integration of diabetes technology into Hajj care protocols and highlight the need for structured pre-Hajj education for PWT1D and HCPs.

## Linked entities

- **Diseases:** type 1 diabetes (MONDO:0005147)

## Full-text entities

- **Genes:** INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}
- **Diseases:** complications (MESH:D008107), type 1 diabetes (MESH:D003922), diabetes (MESH:D003920)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12842451/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12842451/full.md

## References

11 references — full list in the complete paper: https://tomesphere.com/paper/PMC12842451/full.md

---
Source: https://tomesphere.com/paper/PMC12842451